Here are the 10-K annual reports from Certara, Inc. (CERT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CERT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CERT filings page.
Certara, Inc. presents an annual overview of its biosimulation-focused business, strategy, and risks. The company provides modeling, data, AI and regulatory consulting tools that help biopharmaceutical customers design better trials, support drug approvals and manage regulatory submissions.
Certara’s software and services have been used by more than 2,600 organizations, with over 160,000 licensed users and 20 global drug regulators. Customers include 38 of the top 40 biopharmaceutical companies by R&D spend. As of February 17, 2026, Certara had 159,139,562 common shares outstanding.
The report highlights growing use of model‑informed drug development, expansion into AI-enabled workflows and the 2024 acquisition of Chemaxon to strengthen discovery informatics. It also outlines extensive risk factors, including regulatory shifts, R&D spending pressures, competition, AI-related challenges, FDA operational disruptions and macroeconomic headwinds.